New glaucoma drug
The single most exciting development project is latanoprostene bunod (LBN, Vyzulta), a prostaglandin analogue that acts as a nitric oxide donor. The agent has two mechanisms of action, the familiar latanoprost effect of increasing uveoscleral outflow, with nitric oxide donation acting to increase outflow through the trabecular meshwork.
Two recent phase III studies found that LBN provided a mean reduction in IOP of 7.5-9.1 mm Hg over 3 months of treatment, a result that was statistically superior to timolol between 2 and 12 weeks. There were no significant safety findings from either trial.
“We are excited to be working on an investigational product that provides two mechanisms of action to deal with elevated ocular pressure,” Valorie said. “We are looking forward to the potential and the possibility for this agent to serve both patients and physicians in the future.”